CP and COVID-19: Moreover, there are randomised studies reporting no beneficial effect, although CP therapy was not specifically given to patients with viraemia in these trials.16–18 There is thus a need for a randomised clinical trial that focuses on a population at high risk of severe COVID-19 (ie, patients with viraemia in early disease) and on which plasma to give and how (preferably neutralising antibodies of at least 1:640 and one plasma bag infused daily until clearance of viraemia occurs).